FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy
/
DateNov 05 2025
Heidelberg, Germany – November 6, 2025. PRECISIS GmbH today announced that the U.S. Food & Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval... Read More →


















